Retour au portail Europarl

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (sélectionné)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Ce document n'est pas disponible dans votre langue. Il vous est proposé dans une autre langue parmi celles disponibles dans la barre des langues.

Parliamentary questions
PDF 44kWORD 24k
17 June 2013
E-007046-13
Question for written answer E-007046-13
to the Commission
Rule 117
Claudiu Ciprian Tănăsescu (S&D) , Anna Rosbach (ECR)

 Subject:  Spread of MDR-TB in Europe
 Answer in writing 

Nearly a quarter of the world’s cases of multi-drug-resistant tuberculosis occur in the WHO European Region, posing a threat to both the health of the citizens and the economies of Europe. Where the cost of treating a normal case of TB is around EUR 1 000, the price of treating MDR-TB can be EUR 50 000.

1. If tuberculosis (TB), and especially multi-drug-resistant TB, continue to spread, how many EU citizens will be affected by TB in 10 years’ time?

2. Since the European Commission is supporting the fight against TB mainly by contributing to the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), but the GFATM is currently transitioning out of the European region, how does the Commission plan to address the growing MDR-TB epidemic in Europe?

3. What, in the Commission’s opinion, would be the most effective measures to combat the spread of MDR-TB?

4. In the EU Member States that are hardest hit by MDR-TB, how high a percentage of healthcare expenditure is going towards treating MDR-TB, and what proportion towards preventing it? How can we ensure that the five high burden countries in the EU fight the epidemic adequately ? How can the EU support the five EU high burden countries using existing financial instruments?

5. How many EU funds are currently being used for research into treating, testing and preventing MDR-TB?

 OJ C 81 E, 20/03/2014
Avis juridique - Politique de confidentialité